Pfizer vaccine Prevenar13 for older patients to reach major end point

March 3 (Xinhua) -- Pfizer announced on February 24 that A clinical study of Prevenar13 (Streptococcus Pneumonia13) for patients 65 years of age and older has reached its primary endpoint and two secondary endpointsWilliam Gruber, the company's senior vice president of clinical research on vaccines, said the CAPiTA clinical trial "proves that Prevenar13 can prevent vaccine-type streptococcus in adult patients." "
this study, which recruited about 85,000 patients in the Netherlands, was a major endpoint that demonstrated the effectiveness of Prevenar13 for first-time vaccine-based community-acquired pneumonia (CAP)At the same time, the secondary target for first-time aseptic/non-invasive vaccine TYPE CAP is effective, and the secondary target for the first-time disease of vaccine-type invasive pneumococcaldiseaseis effectivePfizer said detailed clinical trial results will be presented next month at the International Symposium on Pneumococcal and Pneumococcal Diseasesthe drugmaker noted that the CAPiTA study was used to demonstrate the vaccine's benefits for older patients after the FDA granted accelerated approval for the population of this type of patientEmilio AEmini, Pfizer's senior vice president of vaccine development, said the drugmaker would "share data from the U.Sand globaldrugregulators and the Vaccine Technical Committee to help inform possible Prevenar13 labels and use recommended updatedecisions." Mark Schoenbaum, an analyst atInternational Strategic Investment Group, said The application of Prevenar13 in adult patients is expected to generate $1 billion in salesAnalysts expect the product, known as Prevnar13 in the U.S., to generate $4.4 billion in total sales this yearthe vaccine was first approved in Europe in 2009 for infant , and is now approved for use in more than 120 countries, including the United States and Japan In addition, Prevenar13 is licensed for adults 50 years and older in more than 90 countries, and for
older children and 6 to 17 years of age in the United States and Europe Last year, Prevenar13 was also approved for use in Adults aged 18 to 49 in Europe